PR Newswire CAMBRIDGE, Mass., Nov. 4, 2024 Topline Data Readout From Part 1 and Part 2 Expected in December 2024 CAMBRIDGE, Mass., Nov. 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology ...
PR Newswire CINCINNATI, Nov. 4, 2024 CINCINNATI, Nov. 4, 2024 /PRNewswire/ -- Sense Neuro Diagnostics, a leader in developing technology for the diagnosis and monitoring of brain injuries, today announced it has been awarded a $2 million ...
PR Newswire TAIPEI, Nov. 4, 2024 TAIPEI, Nov. 4, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TW) reports completion and successful top-line results from CPN-303, a Phase 3 clinical study of APP13007 (GPN00833), conducted in ...
PR Newswire PALO ALTO, Calif. and CAMBRIDGE, Mass., Oct. 28, 2024 Innovative Assay Aims to Enhance Patient Outcomes through Precision Medicine PALO ALTO, Calif. and CAMBRIDGE, Mass., Oct. 28, 2024 /PRNewswire/ -- DELFI Diagnostics, ...
PR Newswire BROOKLYN, N.Y., Oct. 28, 2024 Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive Treatment BROOKLYN, N.Y., Oct. 28, 2024 /PRNewswire/ -- Vensica ...
PR Newswire ALBUQUERQUE, N.M., Oct. 28, 2024 ALBUQUERQUE, N.M., Oct. 28, 2024 /PRNewswire/ -- T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today that ...
PR Newswire MORRISVILLE, N.C., Oct. 25, 2024 MORRISVILLE, N.C., Oct. 25, 2024 /PRNewswire/ -- Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology ...
PR Newswire BOSTON, Oct. 24, 2024 Study site selection and finalization of clinical trial agreement final step toward initiation of RVL-001 proof-of-concept clinical studies early next year BOSTON, Oct. 24, 2024 /PRNewswire/ -- Unravel ...
PR Newswire LAS VEGAS, Oct. 22, 2024 JAK inhibitors are a class of medications that work by blocking Janus kinases (JAKs), enzymes that are involved in the signaling pathways of various cytokines and growth factors. JAK inhibitors offer a ...
PR Newswire AACHEN, Germany, Oct. 22, 2024 AACHEN, Germany, Oct. 22, 2024 /PRNewswire/ -- Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor ...
Vanderbilt’s Phase I trial of VU319 demonstrates promising results for Alzheimer’s and schizophrenia
Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with undetectable MRD.
Hypovolemic phlebotomy, removing 10% of blood before liver surgery, can cut transfusion needs by 50%, offering a safe, cost-effective way to reduce surgery risks.
Felzartamab, an investigational antibody, reduces triggers linked to IgA nephropathy, an autoimmune kidney disease, suggesting lasting clinical benefits.
Discover how FarrSight ®-Twin technology utilizes digital twins to revolutionize cancer clinical trials by simulating patient responses.
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers